The Safety Properties of Sodium Alginate and its Derivatives

Authors

  • Laleh Sharfi Uro-oncology Research center, Tehran University of Medical Sciences, Tehran, Iran
  • Mohammad Reza Nowroozi Uro-oncology Research center, Tehran University of Medical Sciences, Tehran, Iran
  • Galina Smirnova Institute of Biology of the University of Latvia, Riga, Latvia and Institute of Innovative Biomedical Technology, Riga, Latvia
  • Anna Fedotova Institute of Innovative Biomedical Technology, Riga, Latvia
  • Dmitry Babarkin Institute of Innovative Biomedical Technology, Riga, Latvia
  • Abbas Mirshafiey Department of Immunology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

DOI:

https://doi.org/10.14738/bjhmr.111.16126

Abstract

Alginate is a biomaterial with a vast use in biomedicine, food and pharmaceutical industry due to its advantageous properties such as abundance, biocompatibility and easiness of gelation. The Food and Drug Administration (FDA) has confirmed some alginates salts and related derivative to “generally regarded as safe” components for oral use. According to the vast use of alginate as a harmless agent in food and pharmaceutical industries, logically its hydrolysate and ultimately its residues including Mannuronic and Guluronic acids, as alginate hydrolysate components are safe and non-toxic ingredients. In this regard, a number of studies have been conducted to reveal the safety of these agents. Hear, we aimed to review the safety of sodium alginate and its hydrolysate in the literature. In conclusion, the outcomes of acute and chronic toxicity studies indicate that the sodium alginate and its hydrolysate have a high safety profile when administered orally to animals.

Downloads

Published

2024-02-20

How to Cite

Sharfi, L., Nowroozi, M. R., Smirnova, G., Fedotova, A., Babarkin, D., & Mirshafiey, A. (2024). The Safety Properties of Sodium Alginate and its Derivatives. British Journal of Healthcare and Medical Research, 11(1), 263–274. https://doi.org/10.14738/bjhmr.111.16126